Cefuroxime for Salmonella Infections
Cefuroxime is NOT a first-line agent for Salmonella infections and should generally be avoided in favor of fluoroquinolones (for susceptible isolates) or ceftriaxone. 1, 2
FDA-Approved Indications
- The FDA label for cefuroxime does not list Salmonella as an approved indication for treatment 2.
- While the label notes that Salmonella spp. demonstrate in vitro susceptibility (MIC ≤ susceptible breakpoint in ≥90% of isolates), it explicitly states: "the efficacy of cefuroxime in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials" 2.
Guideline-Based Recommendations
- For extra-intestinal Salmonella infections (including renal abscesses, septicemia): Fluoroquinolones (e.g., ciprofloxacin) are first-line for susceptible isolates 1.
- Ceftriaxone is the preferred alternative cephalosporin, particularly in children, pregnant women, or when fluoroquinolone resistance is documented 1.
- Cefuroxime is conspicuously absent from current treatment guidelines for Salmonella 1.
Evidence on Cephalosporin Efficacy
Ceftriaxone vs. Other Agents
- Ceftriaxone performs comparably to azithromycin and fluoroquinolones for enteric fever, with low-certainty evidence suggesting possible decreased clinical failure compared to azithromycin (RR 0.42,95% CI 0.11-1.57) and shorter time to defervescence (mean difference -0.52 days) 3.
- A 2025 systematic review identified azithromycin and ceftriaxone as the most effective agents for Salmonella infections based on hospital length of stay and fever resolution 4.
Cefuroxime-Specific Data
- Cefuroxime has significantly lower affinity for PBP3SAL, an alternative penicillin-binding protein that Salmonella expresses intracellularly in acidic environments 5.
- This reduced affinity translates to decreased effectiveness against intracellular Salmonella compared to cephalosporins like cefotiam that bind PBP3SAL more effectively 5.
- Limited older data (1996) showed cefuroxime axetil 500 mg twice daily was effective for enteric fever in 30 adults, but this predates widespread resistance patterns 6.
- One 1984 study used cefuroxime successfully for Salmonella meningitis in two children, but the authors concluded "additional information is necessary before cefuroxime can be recommended for therapy of Salmonella meningitis" 7.
Cefixime Performance
- Cefixime (another second-generation oral cephalosporin) performs poorly compared to fluoroquinolones, with increased clinical failure (RR 13.39), microbiological failure (RR 4.07), relapse (RR 4.45), and longer time to defervescence (+1.74 days) 3.
Clinical Algorithm
For suspected or confirmed Salmonella infection:
- First-line: Fluoroquinolone (ciprofloxacin) if susceptible 1, 4
- Alternative (if fluoroquinolone-resistant or contraindicated): Ceftriaxone 1, 4, 3
- Pediatric/pregnancy: Ceftriaxone or azithromycin 1, 4
- Extensively drug-resistant: Azithromycin 4, 8
- Avoid: Cefuroxime and cefixime due to inferior outcomes 5, 3
Critical Pitfalls
- Do not assume all cephalosporins are equivalent for Salmonella—ceftriaxone (third-generation) has superior efficacy compared to cefuroxime (second-generation) 1, 5, 3.
- Intracellular Salmonella requires agents with PBP3SAL affinity—cefuroxime lacks this property 5.
- Resistance patterns are evolving rapidly, including ceftriaxone-resistant strains emerging in Pakistan; always obtain susceptibility testing 8.
- Blood cultures are mandatory in any patient with diarrhea and fever, especially if immunocompromised, to detect bacteremia 1.